| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.
|
Lancet
|
2012
|
50.94
|
|
2
|
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
|
Lancet
|
2002
|
40.37
|
|
3
|
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.
|
Lancet
|
1990
|
24.72
|
|
4
|
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
|
N Engl J Med
|
2015
|
18.66
|
|
5
|
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).
|
Eur Heart J
|
2013
|
12.73
|
|
6
|
Global burden of blood-pressure-related disease, 2001.
|
Lancet
|
2008
|
11.09
|
|
7
|
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes.
|
N Engl J Med
|
2002
|
5.72
|
|
8
|
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
|
N Engl J Med
|
2016
|
5.24
|
|
9
|
Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'.
|
Kidney Int
|
2013
|
2.34
|
|
10
|
Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
|
Lancet Diabetes Endocrinol
|
2015
|
1.69
|
|
11
|
European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring.
|
J Hypertens
|
2014
|
1.58
|
|
12
|
Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression.
|
J Hypertens
|
2012
|
1.45
|
|
13
|
Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?
|
J Hypertens
|
2015
|
1.42
|
|
14
|
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
|
Diabetes Care
|
2016
|
1.33
|
|
15
|
Validation of the mobil-O-Graph: 24 h-blood pressure measurement device.
|
Blood Press Monit
|
2010
|
1.19
|
|
16
|
Current challenges in the clinical management of hypertension.
|
Nat Rev Cardiol
|
2011
|
0.89
|
|
17
|
Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis.
|
Kidney Int
|
2016
|
0.87
|
|
18
|
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
|
Diabetes Care
|
2016
|
0.85
|
|
19
|
Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression.
|
J Hypertens
|
2014
|
0.84
|
|
20
|
Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria.
|
Clin Sci (Lond)
|
2016
|
0.78
|
|
21
|
Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics.
|
Int J Cardiol
|
2015
|
0.78
|
|
22
|
Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators.
|
Hypertension
|
2016
|
0.78
|
|
23
|
[Cardiovascular risk study in patients with renin-angiotensin system blockade by means of the proteone of circulating extracellular vesicles].
|
Hipertens Riesgo Vasc
|
2015
|
0.75
|
|
24
|
Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease.
|
Diabetes Care
|
2016
|
0.75
|